A major new study published in JAMA Network Open suggests that GLP-1 receptor agonists, widely used for weight loss and type 2 diabetes, may also improve survival outcomes in women with breast cancer.
Researchers analyzed data from more than 841,000 breast cancer patients and found that women using GLP-1 medications experienced lower rates of all-cause mortality and cancer recurrence compared with certain nonusers and patients taking older diabetes treatments.
The findings are drawing attention because medications such as semaglutide and tirzepatide are already widely prescribed for obesity and diabetes management. Scientists are now exploring whether these drugs could eventually play a supportive role in oncology care.
GLP-1 receptor agonists, commonly called GLP-1 drugs, are medications designed to improve blood sugar control and support weight loss. Popular examples include:
These medications work by mimicking a hormone that regulates appetite, insulin secretion, and digestion. Over the past few years, GLP-1 therapies have become increasingly popular for obesity treatment and type 2 diabetes management.
Researchers have also begun investigating whether the metabolic benefits of these medications could influence cancer outcomes.
Previous studies have consistently shown that obesity and type 2 diabetes are linked to poorer breast cancer outcomes. Women with these conditions often face:
Excess body fat can create hormonal and metabolic conditions that may encourage tumor growth. Because GLP-1 medications help reduce weight and improve insulin sensitivity, researchers wanted to determine whether they could also influence long-term cancer survival.
The new cohort study evaluated electronic health record data from 68 healthcare organizations across the United States. Investigators reviewed records from women diagnosed with stage I to III breast cancer between 2006 and 2023.
After statistical matching, researchers compared several patient groups:
The primary outcome measured was all-cause mortality over a 10-year follow-up period. Researchers also examined recurrence-free survival, which refers to how long patients remained free from metastatic cancer recurrence.
The study reported several notable findings.
Among breast cancer patients with obesity, GLP-1 medication use was associated with:
Researchers reported a hazard ratio of 0.35 for all-cause mortality, suggesting significantly lower risk compared with nonusers.
Among women with type 2 diabetes, GLP-1 users had substantially better outcomes than patients using insulin or metformin alone.
The study found:
Interestingly, researchers found fewer significant differences when GLP-1 medications were compared with SGLT2 inhibitors, another modern diabetes drug class associated with cardiovascular benefits.
This suggests both medication categories may provide metabolic advantages that could influence cancer outcomes.
The study does not prove that GLP-1 medications directly prevent cancer recurrence. However, scientists believe several biological mechanisms could explain the association.
Potential factors include:
Obesity is strongly associated with worse breast cancer outcomes. Significant weight loss may reduce inflammatory pathways and hormone-related tumor growth signals.
High insulin levels may promote cancer progression in some patients. GLP-1 therapies help regulate blood sugar and reduce insulin resistance.
Chronic inflammation has been linked to cancer progression. Some studies suggest GLP-1 drugs may lower inflammatory activity.
Preclinical laboratory research has shown that GLP-1 signaling may inhibit tumor growth in certain cancer models, including breast cancer cells.
Although the findings are promising, experts caution that the research has important limitations.
This was a retrospective observational study, meaning researchers reviewed existing health records rather than conducting a randomized clinical trial.
As a result:
Researchers also noted that some long-term survival estimates became less precise because many patients were censored after five years.
The study adds to growing interest in the relationship between metabolic health and cancer outcomes. However, experts stress that GLP-1 medications are not currently approved specifically for breast cancer treatment or recurrence prevention.
Patients should not start, stop, or switch medications solely based on this research without speaking to their healthcare provider.
Still, the findings may encourage future clinical trials examining whether GLP-1 therapies could support cancer survivorship strategies in women with obesity or diabetes.
Researchers say more work is needed to understand:
Future randomized controlled trials will be critical before doctors can establish formal cancer-related recommendations.
This large-scale study suggests that GLP-1 receptor agonists may be associated with improved survival and lower recurrence risk in certain women with breast cancer, especially those with obesity or type 2 diabetes.
While the findings are encouraging, they do not confirm that GLP-1 drugs directly prevent cancer progression. Researchers emphasize that prospective clinical trials are still needed.
As GLP-1 medications continue reshaping obesity and diabetes care, scientists are increasingly exploring their broader role in long-term health outcomes, including cancer survivorship.
Tatum KL, Dahman B, Stevenson A, et al. “Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer.” JAMA Network Open Published May 11, 2026.
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. The study discussed is observational research and does not prove causation. Always consult a qualified healthcare professional before making decisions about medications, cancer treatment, diabetes management, or weight loss therapies.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.